Liraglutide for HIV-associated Neurocognitive Disorder
Part of paid clinical trials in Philadelphia, Pennsylvania.
- Sponsor
- Temple University
- Study ID
- NCT02743598
- Phase
- PHASE4
- Status
- Terminated
Conditions
- Diabetes Mellitus Type 2
- HIV Infection
- Metabolic Syndrome
- Obesity
- Overweight
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Liraglutide — DRUG
Study Details
This study will test the effect of liraglutide on cognitive function in HIV-infected overweight or obese subjects with type 2 diabetes.
Key Dates
- Start date
- Sep 30, 2016
- Status verified
- Jul 2022
- Primary completion
- Jun 1, 2018
- Completion
- Sep 30, 2018
Study Design
- Enrollment
- 4 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Liraglutide
Primary Outcome Measure
Neurocognitive performance- change in global cognitive scores on a standard neuropsychological profile [ Time Frame: 6 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cherie Vaz | Philadelphia | Pennsylvania | 19140 | - |
Find similar trials in Philadelphia, PA
By condition
By research site
Related Studies
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV RemissionPHASE1/PHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · La Jolla, California
- Probiotics and Gut HealthPHASE1/PHASE2 · Recruiting · Penn State University · University Park, Pennsylvania
- Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility StudyRecruiting · AIDS Malignancy Consortium · La Jolla, California
- Pharmacogenetics of Response to GLP1R AgonistsPHASE1 · Recruiting · University of Maryland, Baltimore · Lancaster, Pennsylvania